Efficacy and Safety of Risankizumab in Patients With Moderate to Severe Crohn's Disease With 3 Years of Treatment: Results From the FORTIFY Open-Label Long-Term Extension

被引：0

作者：

Ferrante, M. ^{[1
]}

Panaccione, R. ^{[2
]}

Colombel, J. F. ^{[3
]}

Dubinsky, M. C. ^{[4
]}

Hisamatsu, T. ^{[5
]}

Lindsay, J. O. ^{[6
]}

Song, A. ^{[7
]}

Yao, Y. ^{[8
]}

Zhang, Y. ^{[8
]}

Zambrano, J. ^{[9
]}

Aponte, F. ^{[10
]}

Duan, W. R. ^{[11
]}

D'Haens, G. ^{[12
]}

机构：

[1] Katholieke Univ Leuven, Dept Gastroenterol & Hepatol, Univ Hosp Leuven, Leuven, Belgium

[2] Univ Calgary, Div Gastroenterol & Hepatol, Inflammatory Bowel Dis Unit, Calgary, AB, Canada

[3] Icahn Sch Med Mt Sinai, Dept Med, Henry D Janowitz Div Gastroenterol, New York, NY USA

[4] Icahn Sch Med Mt Sinai, Susan & Leonard Feinstein IBD Ctr, New York, NY USA

[5] Kyorin Univ, Sch Med, Dept Gastroenterol & Hepatol, Tokyo, Japan

[6] Queen Mary Univ London, Ctr Immunobiol Barts, London Sch Med & Dent, London, England

[7] AbbVie, Clin Dev, N Chicago, IL USA

[8] AbbVie, Stat, N Chicago, IL USA

[9] AbbVie, US Med Affairs, N Chicago, IL USA

[10] AbbVie, Int Med Affairs, N Chicago, IL USA

[11] AbbVie, Med Safety Evaluat, N Chicago, IL USA

[12] Univ Amsterdam, Dept Gastroenterol & Hepatol, Amsterdam UMC, Amsterdam, Netherlands

来源：

JOURNAL OF CROHNS & COLITIS | 2025年 / 19卷

关键词：

D O I：

10.1093/ecco-jcc/jjae190.0055

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

DOP016

引用

页码：i109 / i111

页数：3

共 50 条

[41] Long-term safety and efficacy of risankizumab for the treatment of moderate- to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up
Papp, Kim A.
Blauvelt, Andrew
Puig, Lluis
Ohtsuki, Mamitaro
Beissert, Stefan
Gooderham, Melinda
Amin, Ahmad Z.
Liu, Jie
Wu, Tianshuang
Azam, Tofial
Stakias, Vassilis
Espaillat, Ramon
Sinvhal, Ranjeeta
Soliman, Ahmed M.
Pang, Yinuo
Chen, Michael M.
Lebwohl, Mark G.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (06) : 1149 - 1158
[42] Safety of long-term dupilumab treatment in adults with moderate-to-severe atopic dermatitis: Results from an open-label extension (OLE) trial up to 4 years
Wollenberg, Andreas
Soong, Weily
Goooderham, Melinda
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB106 - AB106
[43] Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn's disease in children: REACH open-label extension
Hyams, Jeffrey
Walters, Thomas D.
Crandall, Wallace
Kugathasan, Subra
Griffiths, Anne
Blank, Marion
Johanns, Jewel
Lang, Yinghua
Markowitz, James
Cohen, Stanley
Winter, Harland S.
Veereman-Wauters, Gigi
Ferry, George
Baldassano, Robert
CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (03) : 651 - 662
[44] Long-Term Safety and Efficacy of Olokizumab in Patients with Rheumatoid Arthritis - Results of an Open-Label Extension Study
Feist, Eugen
Nasonov, Evgeny
Luggen, Michael
Fatenejad, Saeed
Grishin, Sergey
Samsonov, Mikhail
Fleischmann, Roy
ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 603 - 606
[45] Long-Term Safety and Efficacy of Bapineuzumab in Patients with Mild-to-Moderate Alzheimer's Disease: A Phase 2, Open-Label Extension Study
Salloway, Stephen
Marshall, Gad A.
Lu, Ming
Brashear, H. Robert
CURRENT ALZHEIMER RESEARCH, 2018, 15 (13) : 1231 - 1243
[46] Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn's disease
Watanabe, Mamoru
Hibi, Toshifumi
Mostafa, Nael M.
Chao, Jingdong
Arora, Vipin
Camez, Anne
Petersson, Joel
Thakkar, Roopal
JOURNAL OF CROHNS & COLITIS, 2014, 8 (11): : 1407 - 1416
[47] ABP 501 Long-Term Safety/Efficacy: Interim Results from an Open-Label Extension Study
Cohen, Stanley
Pablos, Jose L.
Zhang, Nan
Rizzo, Warren
Muller, Gerhard
Padmanaban, Devi
Kivitz, Alan
Matsumoto, Alan K.
Kaur, Primal
ARTHRITIS & RHEUMATOLOGY, 2016, 68
[48] LONG-TERM EFFICACY AND SAFETY OF LANADELUMAB: FINAL RESULTS FROM THE HELP OPEN-LABEL EXTENSION STUDY
Banerji, A.
Hao, J.
Yu, M.
Bernstein, J.
Johnston, D.
Riedl, M.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2020, 125 (05) : S21 - S21
[49] On-Body Injector Administration of Risankizumab for Treatment of Moderate-to-Severe Crohn's Disease: Data From the Fortify Open-Label Longitudinal Real-Life Handling Substudy
Loftus, Edward, Jr.
Griffith, Jenny
Neimark, Ezequiel
Song, Alexandra
Wallace, Kori
Nannapaneni, Sujani
Zhou, Ji
Andresen, Rachel
Kligys, Kristina
Liao, Xiaomei
Dubinsky, Marla
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 : S10 - S10
[50] Laboratory safety of long-term dupilumab treatment in adults with moderate-to-severe atopic dermatitis: Results from an open-label extension (OLE) study
Blauvelt, Andrew
Wollenberg, Andreas
Beck, Lisa A.
Chen, Zhen
Zhang, Meng
Khokhar, Faisal A.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB142 - AB142

← 1 2 3 4 5 →